Semaglutide for managing overweight and obesity

2.1 Semaglutide (Wegovy, Novo Nordisk) is 'indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m² (obesity), or ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity'.

2.2 The dosage schedule is available in the summary of product characteristics for semaglutide.

2.3 The list price of semaglutide (Wegovy) 2.4 mg is £175.80 per pack, of 1.7 mg is £124.53 per pack, and of 0.25 mg, 0.5 mg and 1.0 mg is £73.25 per pack (excluding VAT; company communication). Each pack contains 1 pen that delivers 4 doses.

2.4 The company has a commercial arrangement. This makes semaglutide available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.